Back to top
more

BioXcel Therapeutics (BTAI)

(Real Time Quote from BATS)

$2.18 USD

2.18
441,401

+0.09 (4.31%)

Updated May 13, 2024 03:47 PM ET

After-Market: $2.18 0.00 (0.00%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for BioXcel Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 65 194 233 213 32
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 2 2 0 0 0
Other Current Assets 5 7 4 4 2
Total Current Assets 72 203 237 217 34
Net Property & Equipment 1 1 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 1 0 0 0
Total Assets 74 206 239 220 36
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 14 10 5 4 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 13 22 11 7 3
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 1 1 0 0
Total Current Liabilities 27 33 17 12 8
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 101 93 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 2 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 130 129 18 13 10
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 534 488 467 346 84
Retained Earnings -591 -412 -246 -139 -57
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -57 77 222 207 27
Total Liabilities & Shareholder's Equity 74 206 239 220 36
Total Common Equity -57 77 222 207 27
Shares Outstanding 29.90 28.00 27.90 24.30 18.00
Book Value Per Share -1.89 2.74 7.95 8.51 1.49

Fiscal Year End for BioXcel Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 74 65 90 128 166
Receivables 0 0 1 0 0
Notes Receivable 0 0 0 0 0
Inventories 2 2 2 2 2
Other Current Assets 4 5 6 8 10
Total Current Assets 81 72 99 138 177
Net Property & Equipment 1 1 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 1
Total Assets 82 74 100 140 180
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 17 14 11 11 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 14 13 27 22 20
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 2 1 1
Total Current Liabilities 31 27 39 35 29
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 102 101 99 97 95
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 21 2 2 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 155 130 141 134 127
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 545 534 528 524 517
Retained Earnings -617 -591 -568 -518 -464
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -72 -57 -41 6 53
Total Liabilities & Shareholder's Equity 82 74 100 140 180
Total Common Equity -72 -57 -41 6 53
Shares Outstanding 37.00 29.90 29.20 29.10 29.00
Book Value Per Share -1.96 -1.89 -1.39 0.20 1.83